1171P A phase II theranostic study with osimertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC) progressing on EGFR tyrosine kinase inhibitors (TKI) and undetectable EGFR T790M (THEROS)

Abstract

Personalized sequences of targeted agents instructed by the detection of resistance mechanisms by rebiopsy or liquid biopsy enable impressive survival outcomes in patients with advanced NSCLC harboring therapeutically tractable oncogenic drivers. Overcoming EGFR T790M-associated TKI resistance with osimertinib is a prime example of this approach. Limitations of current biomarkers may deny patients this treatment option. We hypothesized that early detection of metabolic response by FDG-PET identifies additional patients benefitting from sequenced osimertinib.